Cumberland Pharmaceuticals Inc. (CPIX)

From the record

Cumberland Pharmaceuticals Inc.'s filings since 2017 show 5 warning events: an auditor change (8-K item 4.01, 5 times, the latest 2023-06-02) (its current reports).

From the record

Cumberland Pharmaceuticals Inc.'s 10 filed years say what it did: revenue went from $32 million in fiscal 2016 to $45 million in fiscal 2025, up 3.6% a year; it rose in 5 of 9 years; the deepest fall was 29% from fiscal 2017 to fiscal 2018; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Cumberland Pharmaceuticals Inc.'s diluted share count grew about 0.7% a year, and dividends and buybacks returned about 15% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Cumberland Pharmaceuticals Inc. lost about 12 cents for every dollar of shareholders' money, and gross profitability: its products earned about 49 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 68 cents per dollar of assets, and net share issuance: its share count grew 5.6% over the year (the filed statements).

From the record

Cumberland Pharmaceuticals Inc.'s standing among 315 graded names in its industry family: revenue of $45 million in fiscal 2025 ranks in the top 46% by size; a net margin of -6.4% ranks in the top 28%; revenue growth of 2% a year over the last 3 filed years ranks in the bottom 41% (its annual reports).

From the record

Cumberland Pharmaceuticals Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Kazimi, A J (Chairman and CEO, as filed), filing under that title since 2009-08-11, 17.3 years (top 4% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 9.2 years (top 12%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 10 people in charge now (top 6%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Cumberland Pharmaceuticals Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $11 million against no long-term debt tagged leaves 14.9% of its assets as net cash, bottom 33% of its family; cash from operations less capital spending is 10.9% of revenue (top 20%); a gross margin of 85% (top 27%); research spending of 12.5% of revenue (bottom 17%) (its annual report).

From the record

Cumberland Pharmaceuticals Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 2% a year over the last three filed years against 3.6% over all 10, slowing (bottom 50% of its family); the newest year grew 17.6% (top 39%); research spending grew -5.9% a year (bottom 39%); capital spending grew -1.4% a year (top 39%) (its annual reports). Cumberland Pharmaceuticals Inc. reported 8 product lines in fiscal 2025: Product Sancuso at $12 million (27%), Product Kristalose at $11 million (24%), Product Vibativ at $9 million (21%), and 5 more; 4 of 7 grew against the year before (its annual report).

From the record

Cumberland Pharmaceuticals Inc.'s newest year against its own record: revenue of $45 million in fiscal 2025 came in 23.8% above the $36 million its prior three years' pace pointed to (top 26% of its family); net income of $3 million against a prior three-year average of $6 million (top 29%); a net margin of -6.4% against -15.4% before (bottom 48%) (its annual reports).